Description:
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the development of atherosclerosis and heart failure caused by ischemic conditions. Losmapimod did not cause an improvement in exercise tolerance or lung function, despite being well-tolerated in this COPD population. The p38 MAPK inhibitor losmapimod (GW856553) attenuates the pro-inflammatory response in humans by reducing PIC production.
- Molecular Weight: 383.467
- Molecular Formula: C22H26FN3O2
Purity: 98%
Canonical SMILES:
CC1=C(C=C(C=C1C2=NC=C(C=C2)C(=O)NCC(C)(C)C)C(=O)NC3CC3)F
InChI:
InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
InChIKey: KKYABQBFGDZVNQ-UHFFFAOYSA-N
- Appearance: White Solid Powder
Synonyms:
Losmapimod; GW856553; GW-856553; GW 856553 GSK-AHAB; GW856553X; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
More details are to be found on supplier website
